[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed — best-supported diagnosis is CIDP, not Lewis-Sumner\\n\\nKey stem clues: 6 months of progressive weakness; symmetric bilateral ulnar territory motor and sensory deficits; exam explicitly “symmetric weakness”; conduction studies with demyelinating features (conduction block at elbow, prolonged distal motor latencies, temporal dispersion); elevated CSF protein with normal cell count (albuminocytologic dissociation); negative anti-ganglioside antibodies.\\n\\nThese findings fit chronic inflammatory demyelinating polyneuropathy, which typically presents as a chronic, symmetric sensorimotor neuropathy with demyelinating NCS and albuminocytologic dissociation. In contrast, Lewis-Sumner (MADSAM) characteristically has multifocal, asymmetric involvement mimicking mononeuropathies. The stem twice emphasizes symmetry and confines findings to a single nerve distribution bilaterally, which does not support an asymmetric multifocal pattern.\\n\\nOther options: MMN is purely motor and usually anti-GM1 positive; lupus mononeuritis multiplex is axonal and multifocal; HNPP shows hereditary pattern and typical compression sites without classic CIDP CSF findings.\\n\\nMain medical issue: explanation correctly describes MADSAM vs CIDP but contradicts the actual symmetric findings in the stem.\\n\\nMinimal fix: Change the keyed answer to B (CIDP) and adjust explanation accordingly, or revise the stem to clearly describe asymmetric multifocal involvement to fit Lewis-Sumner syndrome.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed — best-supported diagnosis is CIDP, not Lewis-Sumner\n\nKey stem clues: 6 months of progressive weakness; symmetric bilateral ulnar territory motor and sensory deficits; exam explicitly “symmetric weakness”; conduction studies with demyelinating features (conduction block at elbow, prolonged distal motor latencies, temporal dispersion); elevated CSF protein with normal cell count (albuminocytologic dissociation); negative anti-ganglioside antibodies.\n\nThese findings fit chronic inflammatory demyelinating polyneuropathy, which typically presents as a chronic, symmetric sensorimotor neuropathy with demyelinating NCS and albuminocytologic dissociation. In contrast, Lewis-Sumner (MADSAM) characteristically has multifocal, asymmetric involvement mimicking mononeuropathies. The stem twice emphasizes symmetry and confines findings to a single nerve distribution bilaterally, which does not support an asymmetric multifocal pattern.\n\nOther options: MMN is purely motor and usually anti-GM1 positive; lupus mononeuritis multiplex is axonal and multifocal; HNPP shows hereditary pattern and typical compression sites without classic CIDP CSF findings.\n\nMain medical issue: explanation correctly describes MADSAM vs CIDP but contradicts the actual symmetric findings in the stem.\n\nMinimal fix: Change the keyed answer to B (CIDP) and adjust explanation accordingly, or revise the stem to clearly describe asymmetric multifocal involvement to fit Lewis-Sumner syndrome.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 32-week pregnant woman with severe hypertension, hemolysis (schistocytes, high LDH), thrombocytopenia, elevated AST and creatinine → postpartum thrombotic microangiopathy. Lack of improvement/worsening after delivery and ADAMTS13 activity 58% argue against TTP (<10%) and against purely pregnancy-related HELLP/preeclampsia, pointing toward complement-mediated TMA (atypical HUS), for which eculizumab is indicated. Among options, a complement factor H mutation directly documents complement dysregulation and is the strongest support for initiating complement-blocking therapy.\\nAlternative choices: Positive DAT (A) suggests autoimmune hemolysis/Evans syndrome, not a primary indication for eculizumab. Elevated sFlt-1 (C) indicates preeclampsia/placental dysfunction, for which definitive therapy is delivery, already done. Low C3 with normal C4 (D) is suggestive of alternative pathway activation but is less specific than a defined pathogenic CFH mutation. Anti-phospholipid antibodies (E) suggest APS/catastrophic APS, managed with anticoagulation and other immunomodulation, not primarily eculizumab.\\nMain medical issues: Minor—genetic testing results are rarely available acutely, but question asks about strongest supporting finding, not real-time practicality.\\nMinimal fix: Clarify stem as “Which additional diagnostic finding, if present, would most specifically support complement-mediated TMA requiring eculizumab?”\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 32-week pregnant woman with severe hypertension, hemolysis (schistocytes, high LDH), thrombocytopenia, elevated AST and creatinine → postpartum thrombotic microangiopathy. Lack of improvement/worsening after delivery and ADAMTS13 activity 58% argue against TTP (<10%) and against purely pregnancy-related HELLP/preeclampsia, pointing toward complement-mediated TMA (atypical HUS), for which eculizumab is indicated. Among options, a complement factor H mutation directly documents complement dysregulation and is the strongest support for initiating complement-blocking therapy.\nAlternative choices: Positive DAT (A) suggests autoimmune hemolysis/Evans syndrome, not a primary indication for eculizumab. Elevated sFlt-1 (C) indicates preeclampsia/placental dysfunction, for which definitive therapy is delivery, already done. Low C3 with normal C4 (D) is suggestive of alternative pathway activation but is less specific than a defined pathogenic CFH mutation. Anti-phospholipid antibodies (E) suggest APS/catastrophic APS, managed with anticoagulation and other immunomodulation, not primarily eculizumab.\nMain medical issues: Minor—genetic testing results are rarely available acutely, but question asks about strongest supporting finding, not real-time practicality.\nMinimal fix: Clarify stem as “Which additional diagnostic finding, if present, would most specifically support complement-mediated TMA requiring eculizumab?”", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Symptomatic obstructive HCM (LVOT gradient 85 mmHg) with SAM-related moderate MR, recurrent appropriate ICD shocks for VT despite maximally tolerated beta-blocker and disopyramide, septal thickness 22 mm, and extensive LGE (18%) on MRI. These indicate high arrhythmic risk plus a strong indication for septal reduction therapy, ideally allowing mitral repair.\\nOption B (surgical septal myectomy with mitral valve repair) is best: it directly relieves LVOT obstruction, reduces wall stress and ischemia that contribute to ventricular arrhythmias, and treats SAM-related MR, without adding myocardial scar. Alcohol septal ablation (A) intentionally creates infarct/scar, which in a patient with already extensive LGE and VT risk is plausibly proarrhythmic and usually avoided in this context.\\nVT catheter ablation (C) treats episodes but not underlying hemodynamic driver; can be adjunctive but not the primary intervention to reduce burden here. Adding amiodarone (D) is guideline-acceptable for shock reduction but does not address obstruction and carries long-term toxicity; myectomy is more definitive. Transplant evaluation (E) is premature.\\nMinimal fix: Explicitly state he has limiting obstructive symptoms despite optimal medical therapy to clarify guideline-class indication for surgical myectomy.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Symptomatic obstructive HCM (LVOT gradient 85 mmHg) with SAM-related moderate MR, recurrent appropriate ICD shocks for VT despite maximally tolerated beta-blocker and disopyramide, septal thickness 22 mm, and extensive LGE (18%) on MRI. These indicate high arrhythmic risk plus a strong indication for septal reduction therapy, ideally allowing mitral repair.\nOption B (surgical septal myectomy with mitral valve repair) is best: it directly relieves LVOT obstruction, reduces wall stress and ischemia that contribute to ventricular arrhythmias, and treats SAM-related MR, without adding myocardial scar. Alcohol septal ablation (A) intentionally creates infarct/scar, which in a patient with already extensive LGE and VT risk is plausibly proarrhythmic and usually avoided in this context.\nVT catheter ablation (C) treats episodes but not underlying hemodynamic driver; can be adjunctive but not the primary intervention to reduce burden here. Adding amiodarone (D) is guideline-acceptable for shock reduction but does not address obstruction and carries long-term toxicity; myectomy is more definitive. Transplant evaluation (E) is premature.\nMinimal fix: Explicitly state he has limiting obstructive symptoms despite optimal medical therapy to clarify guideline-class indication for surgical myectomy.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle-aged woman with dermatomyositis, now with progressive dyspnea and new ground-glass opacities with consolidation plus reduced FVC/DLCO and lymphocytic BAL, strongly suggesting active inflammatory interstitial lung disease. Anti-MDA5 positivity is specifically associated with rapidly progressive ILD and high mortality, for which aggressive upfront combination immunosuppression is recommended. Option B (triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide) matches current evidence from Japanese and international cohorts for anti-MDA5–associated RP-ILD.\\nOther options: A (steroids + MMF) and C (rituximab + AZA) are plausible for CTD-ILD generally but are considered inadequate compared with triple therapy in this high-risk anti-MDA5 subset. D (nintedanib) is antifibrotic and adjunctive at best, not primary therapy for active inflammatory RP-ILD. E (plasma exchange + IVIG) lacks supportive evidence as standard first-line for anti-MDA5 ILD.\\nMain medical issues: Content is consistent with contemporary rheumatology/pulmonology data; no major inaccuracies. Minor nuance: triple-therapy data come mainly from observational/retrospective studies, but this aligns with current expert practice.\\nMinimal fix: Explicitly state “rapidly progressive interstitial lung disease” in stem to reinforce the intended high-risk phenotype and need for aggressive combination therapy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle-aged woman with dermatomyositis, now with progressive dyspnea and new ground-glass opacities with consolidation plus reduced FVC/DLCO and lymphocytic BAL, strongly suggesting active inflammatory interstitial lung disease. Anti-MDA5 positivity is specifically associated with rapidly progressive ILD and high mortality, for which aggressive upfront combination immunosuppression is recommended. Option B (triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide) matches current evidence from Japanese and international cohorts for anti-MDA5–associated RP-ILD.\nOther options: A (steroids + MMF) and C (rituximab + AZA) are plausible for CTD-ILD generally but are considered inadequate compared with triple therapy in this high-risk anti-MDA5 subset. D (nintedanib) is antifibrotic and adjunctive at best, not primary therapy for active inflammatory RP-ILD. E (plasma exchange + IVIG) lacks supportive evidence as standard first-line for anti-MDA5 ILD.\nMain medical issues: Content is consistent with contemporary rheumatology/pulmonology data; no major inaccuracies. Minor nuance: triple-therapy data come mainly from observational/retrospective studies, but this aligns with current expert practice.\nMinimal fix: Explicitly state “rapidly progressive interstitial lung disease” in stem to reinforce the intended high-risk phenotype and need for aggressive combination therapy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Advanced HIV (CD4 35), confirmed cryptococcal meningitis, high opening pressure at baseline (32 cm H2O), on appropriate induction therapy (liposomal amphotericin B + flucytosine) with daily LPs. At day 10, opening pressure further elevated (38 cm H2O), CSF WBC up (420/μL) but cryptococcal antigen titer falling (1:2048 → 1:1024), plus worsening headache and new CN VI palsy, and no ART yet.\\nThese findings indicate persistent, poorly controlled intracranial hypertension with microbiologic response rather than IRIS or resistance. Best management is to intensify CSF pressure control with more aggressive drainage (choice D), consistent with current guidelines (e.g., more frequent LPs or temporary drain).\\nOther options: A) IRIS requires ART; steroids are harmful in cryptococcal meningitis. B) Antigen titer is decreasing and induction duration is short, arguing against resistance. C) VP shunt is reserved after failure of maximal medical CSF management. E) Immediate ART in cryptococcal meningitis increases risk of IRIS and mortality; standard is to delay 4–6 weeks.\\nMain medical/logical issues: None significant; item is accurate and well discriminated.\\nMinimal fix: Explicitly state that ART has not yet been started (already implied but could be restated).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Advanced HIV (CD4 35), confirmed cryptococcal meningitis, high opening pressure at baseline (32 cm H2O), on appropriate induction therapy (liposomal amphotericin B + flucytosine) with daily LPs. At day 10, opening pressure further elevated (38 cm H2O), CSF WBC up (420/μL) but cryptococcal antigen titer falling (1:2048 → 1:1024), plus worsening headache and new CN VI palsy, and no ART yet.\nThese findings indicate persistent, poorly controlled intracranial hypertension with microbiologic response rather than IRIS or resistance. Best management is to intensify CSF pressure control with more aggressive drainage (choice D), consistent with current guidelines (e.g., more frequent LPs or temporary drain).\nOther options: A) IRIS requires ART; steroids are harmful in cryptococcal meningitis. B) Antigen titer is decreasing and induction duration is short, arguing against resistance. C) VP shunt is reserved after failure of maximal medical CSF management. E) Immediate ART in cryptococcal meningitis increases risk of IRIS and mortality; standard is to delay 4–6 weeks.\nMain medical/logical issues: None significant; item is accurate and well discriminated.\nMinimal fix: Explicitly state that ART has not yet been started (already implied but could be restated).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Older woman with RA on methotrexate/adalimumab develops subacute cognitive decline; MRI with multifocal non‑enhancing white matter lesions, CSF JCV PCR positive → PML. After stopping adalimumab, she worsens clinically within weeks, MRI now shows new peripheral enhancement and edema, and CSF pleocytosis rises with lymphocytic predominance → classic for PML‑associated IRIS following immune reconstitution.\\n\\nThese findings make immune reconstitution inflammatory syndrome the central issue; standard management is high‑dose corticosteroids to dampen harmful inflammatory response while maintaining immune reconstitution, which supports option B.\\n\\nOption A (restart adalimumab) would worsen PML by re‑inducing immunosuppression and is contrary to accepted management. Option C (cidofovir/cytarabine) has not shown benefit in PML and is not recommended. Option D (pembrolizumab) is considered in PML without evidence of immune reconstitution, not in IRIS. Option E (biopsy) is unnecessary with classic imaging, CSF JCV positivity, and temporal association with immune reconstitution.\\n\\nMain medical accuracy issues: none significant; explanations align with current understanding of PML‑IRIS. Minimal fix: Add wording such as “No new systemic symptoms or mass‑like lesion is seen” to further rule out lymphoma and reinforce that biopsy is unnecessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Older woman with RA on methotrexate/adalimumab develops subacute cognitive decline; MRI with multifocal non‑enhancing white matter lesions, CSF JCV PCR positive → PML. After stopping adalimumab, she worsens clinically within weeks, MRI now shows new peripheral enhancement and edema, and CSF pleocytosis rises with lymphocytic predominance → classic for PML‑associated IRIS following immune reconstitution.\n\nThese findings make immune reconstitution inflammatory syndrome the central issue; standard management is high‑dose corticosteroids to dampen harmful inflammatory response while maintaining immune reconstitution, which supports option B.\n\nOption A (restart adalimumab) would worsen PML by re‑inducing immunosuppression and is contrary to accepted management. Option C (cidofovir/cytarabine) has not shown benefit in PML and is not recommended. Option D (pembrolizumab) is considered in PML without evidence of immune reconstitution, not in IRIS. Option E (biopsy) is unnecessary with classic imaging, CSF JCV positivity, and temporal association with immune reconstitution.\n\nMain medical accuracy issues: none significant; explanations align with current understanding of PML‑IRIS. Minimal fix: Add wording such as “No new systemic symptoms or mass‑like lesion is seen” to further rule out lymphoma and reinforce that biopsy is unnecessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with recurrent oral/genital ulcers and bilateral anterior uveitis, HLA‑B51 positive → Behçet disease. She develops central retinal artery occlusion from vasculitis (retinal whitening, cherry-red spot, box-carring). The question explicitly asks for the *immediate intervention to prevent contralateral involvement*, i.e., systemic control of severe ocular Behçet to prevent bilateral blindness.\\nChoice D (high-dose corticosteroids plus infliximab or adalimumab) aligns with current evidence and guidelines as first-line for severe ocular Behçet (especially retinal vasculitis/occlusive disease) to rapidly suppress inflammation and reduce risk of fellow-eye involvement.\\nA is inadequate monotherapy for this severity. B (infliximab alone) under-treats acute, sight-threatening disease; combination with steroids is standard. C (steroids + cyclosporine) is less favored; cyclosporine is now generally second-line/adjunct and carries neurotoxicity risk, especially in Behçet with possible CNS involvement. E targets embolic CRAO, not immunologic vasculitis, and won’t prevent contralateral disease.\\nMain medical accuracy issue(s): None significant; management is contemporary and appropriate. Minimal fix: Clarify in stem that retinal artery occlusion is attributed to retinal vasculitis from Behçet (e.g., add “angiography shows vasculitic changes”) to fully justify ignoring embolic CRAO maneuvers.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with recurrent oral/genital ulcers and bilateral anterior uveitis, HLA‑B51 positive → Behçet disease. She develops central retinal artery occlusion from vasculitis (retinal whitening, cherry-red spot, box-carring). The question explicitly asks for the *immediate intervention to prevent contralateral involvement*, i.e., systemic control of severe ocular Behçet to prevent bilateral blindness.\nChoice D (high-dose corticosteroids plus infliximab or adalimumab) aligns with current evidence and guidelines as first-line for severe ocular Behçet (especially retinal vasculitis/occlusive disease) to rapidly suppress inflammation and reduce risk of fellow-eye involvement.\nA is inadequate monotherapy for this severity. B (infliximab alone) under-treats acute, sight-threatening disease; combination with steroids is standard. C (steroids + cyclosporine) is less favored; cyclosporine is now generally second-line/adjunct and carries neurotoxicity risk, especially in Behçet with possible CNS involvement. E targets embolic CRAO, not immunologic vasculitis, and won’t prevent contralateral disease.\nMain medical accuracy issue(s): None significant; management is contemporary and appropriate. Minimal fix: Clarify in stem that retinal artery occlusion is attributed to retinal vasculitis from Behçet (e.g., add “angiography shows vasculitic changes”) to fully justify ignoring embolic CRAO maneuvers.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6 weeks of progressive bilateral leg weakness and paresthesias following diarrheal illness; areflexia; albuminocytologic dissociation (CSF protein 95 with 1 WBC); NCS showing reduced CMAP amplitudes with preserved velocities and no block (axonal pattern); strongly positive anti-GM1 antibodies; ongoing deterioration with new respiratory compromise after a full 5‑day IVIG course. These findings support an acute motor axonal neuropathy (AMAN) variant of Guillain‑Barré syndrome with treatment failure to initial IVIG.\\nPlasma exchange is an established alternative first-line therapy in GBS and is appropriate when a patient worsens despite IVIG, especially with respiratory compromise. Repeating or delaying another IVIG course (A, E) is not indicated in a deteriorating, intubated patient. High‑dose steroids (C) are ineffective in GBS and may delay recovery. Eculizumab (D) is investigational and not standard of care.\\nMain medical issues: Minor nuance—course length (6 weeks) edges toward subacute but within accepted GBS time frame, and sensory loss is present though AMAN is classically motor; still reasonable board-level simplification.\\nMinimal fix: Clarify “over 4 weeks but less than 8 weeks” as still within accepted GBS onset window or shorten symptom duration to ≤4 weeks to fully align with classic GBS criteria.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6 weeks of progressive bilateral leg weakness and paresthesias following diarrheal illness; areflexia; albuminocytologic dissociation (CSF protein 95 with 1 WBC); NCS showing reduced CMAP amplitudes with preserved velocities and no block (axonal pattern); strongly positive anti-GM1 antibodies; ongoing deterioration with new respiratory compromise after a full 5‑day IVIG course. These findings support an acute motor axonal neuropathy (AMAN) variant of Guillain‑Barré syndrome with treatment failure to initial IVIG.\nPlasma exchange is an established alternative first-line therapy in GBS and is appropriate when a patient worsens despite IVIG, especially with respiratory compromise. Repeating or delaying another IVIG course (A, E) is not indicated in a deteriorating, intubated patient. High‑dose steroids (C) are ineffective in GBS and may delay recovery. Eculizumab (D) is investigational and not standard of care.\nMain medical issues: Minor nuance—course length (6 weeks) edges toward subacute but within accepted GBS time frame, and sensory loss is present though AMAN is classically motor; still reasonable board-level simplification.\nMinimal fix: Clarify “over 4 weeks but less than 8 weeks” as still within accepted GBS onset window or shorten symptom duration to ≤4 weeks to fully align with classic GBS criteria.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: acute disabling ischemic stroke (aphasia, right hemiplegia) within 90 minutes; CT without hemorrhage; CT angiography showing left M1 occlusion; perfusion with large penumbra and small core (ASPECTS 8); patient on warfarin with therapeutic INR 2.8; blood pressure within acceptable range for reperfusion. In current guidelines, IV alteplase is contraindicated when INR >1.7, so IV thrombolysis (A, C) is inappropriate. Reversing warfarin with PCC solely to permit alteplase (C) is not recommended and introduces delay plus added hemorrhage risk. Idarucizumab (D) is specific to dabigatran, not warfarin. Medical management only (E) is substandard given a treatable large-vessel occlusion with favorable imaging. Mechanical thrombectomy is guideline-supported in this setting and is not contraindicated by warfarin, making direct endovascular thrombectomy (B) the single best answer. No internal contradictions or need for unstated assumptions are present.\\nMinimal fix: Explicitly note “on therapeutic warfarin with INR 2.8” in the stem (already implied) and optionally specify ‘per current AHA/ASA guidelines’ to anchor to contemporary practice timelines.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: acute disabling ischemic stroke (aphasia, right hemiplegia) within 90 minutes; CT without hemorrhage; CT angiography showing left M1 occlusion; perfusion with large penumbra and small core (ASPECTS 8); patient on warfarin with therapeutic INR 2.8; blood pressure within acceptable range for reperfusion. In current guidelines, IV alteplase is contraindicated when INR >1.7, so IV thrombolysis (A, C) is inappropriate. Reversing warfarin with PCC solely to permit alteplase (C) is not recommended and introduces delay plus added hemorrhage risk. Idarucizumab (D) is specific to dabigatran, not warfarin. Medical management only (E) is substandard given a treatable large-vessel occlusion with favorable imaging. Mechanical thrombectomy is guideline-supported in this setting and is not contraindicated by warfarin, making direct endovascular thrombectomy (B) the single best answer. No internal contradictions or need for unstated assumptions are present.\nMinimal fix: Explicitly note “on therapeutic warfarin with INR 2.8” in the stem (already implied) and optionally specify ‘per current AHA/ASA guidelines’ to anchor to contemporary practice timelines.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 33-year-old postpartum woman with peripartum cardiomyopathy (PPCM), significant LV systolic dysfunction partially improving on GDMT; question asks which factor most strongly predicts *complete* LV recovery. Among the choices, absence of late gadolinium enhancement (LGE) on cardiac MRI is well-established as a powerful predictor of full LV functional recovery in nonischemic cardiomyopathies including PPCM, as it reflects lack of irreversible fibrosis.\\nLogical assessment: The options are discriminable. TTN truncating variants are associated with worse recovery, not better. BNP normalization and higher baseline EF are favorable but less specific/strong prognosticators than LGE status. Multiparity is a risk factor for developing PPCM, not for recovery. Thus only A fits as the strongest predictor.\\nMedical accuracy: The associations between TTN truncating variants and incomplete recovery, LGE as a marker of scar and poorer prognosis, and multiparity as a risk factor are consistent with current literature. No major inaccuracies.\\nMinimal fix: Explicitly state in the stem that a cardiac MRI has been performed and shows no LGE to better link the tested concept to patient evaluation, or alternatively rephrase the stem to ask, “Which imaging finding…” to clarify intent.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 33-year-old postpartum woman with peripartum cardiomyopathy (PPCM), significant LV systolic dysfunction partially improving on GDMT; question asks which factor most strongly predicts *complete* LV recovery. Among the choices, absence of late gadolinium enhancement (LGE) on cardiac MRI is well-established as a powerful predictor of full LV functional recovery in nonischemic cardiomyopathies including PPCM, as it reflects lack of irreversible fibrosis.\nLogical assessment: The options are discriminable. TTN truncating variants are associated with worse recovery, not better. BNP normalization and higher baseline EF are favorable but less specific/strong prognosticators than LGE status. Multiparity is a risk factor for developing PPCM, not for recovery. Thus only A fits as the strongest predictor.\nMedical accuracy: The associations between TTN truncating variants and incomplete recovery, LGE as a marker of scar and poorer prognosis, and multiparity as a risk factor are consistent with current literature. No major inaccuracies.\nMinimal fix: Explicitly state in the stem that a cardiac MRI has been performed and shows no LGE to better link the tested concept to patient evaluation, or alternatively rephrase the stem to ask, “Which imaging finding…” to clarify intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]